Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biosimilar Tentative Approvals Could Flow From US Supreme Court Case

Executive Summary

If high court decides that biosimilar sponsors must wait until licensure before providing 180-day notice of commercial launch, FDA may face pressure to start granting tentative licenses for 351(k) applications, industry lawyer says.

You may also be interested in...



Tentative Biosimilar Approvals Under Consideration By FDA

Concept could help sponsors who reach approvability but must wait several years before reference product exclusivity expires.

Tentative Biosimilar Approvals A Consideration for the US FDA

Concept could help sponsors who reach approvability but must wait several years before reference product exclusivity expires.

Should A Biosimilar Sponsor Do The 'Patent Dance?' It Depends On Many Things

The amount of exclusivity remaining for a reference product, strength of an innovator's patents and risk of a preliminary injunction are factors that biosimilar sponsors should consider in deciding whether to follow the BPCIA's patent information and exchange procedures, one legal expert suggests.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS120633

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel